Why the study?
The role of Helicobacter pylori screening and eradication in reducing upper gastrointestinal bleeding complications after acute myocardial infarction remains uncertain.
Does routine H. pylori screening reduce upper gastrointestinal bleeding in adults with acute type-1 myocardial infarction?
Does routine H. pylori screening reduce upper gastrointestinal bleeding in adults with acute type-1 myocardial infarction?
The HELP-MI SWEDEHEART trial will determine if routine H. pylori screening reduces upper gastrointestinal bleeding and improves cardiovascular outcomes in patients with acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Leaves open whether routine H. pylori screening reduces GI bleeding or improves outcomes post-MI; HELP-MI SWEDEHEART trial will test this prospectively.
BACKGROUND: The role of Helicobacter pylori (H. pylori) screening and eradication on reducing upper gastrointestinal bleeding (UGIB) complications after acute myocardial infarction (MI) is uncertain. The HELicobacter pylori screening to prevent gastrointestinal bleeding in patients with acute MI (HELP-MI SWEDEHEART) trial aims to determine whether systematic H. pylori screening compared to usual care reduces UGIB, mortality, and cardiovascular outcomes after MI. METHODS: A cluster randomized, crossover, registry-based clinical trial using SWEDEHEART as trial platform for study population definition and source for data collection in combination with nationwide Swedish health data registries. Thirty-five Swedish hospitals, organized into 18 clusters based on percutaneous coronary intervention networks, were randomized to either routine H. pylori screening for adults with acute type-1 MI or usual care. After 1 year, a 2-month blanking period was followed by a crossover to the alternate allocation for 1 year. The trial enrolment was concluded after one additional year of registry-based follow-up. The primary endpoint is UGIB. Secondary endpoints include all-cause death, cardiovascular death, readmission for MI, stroke, or heart failure. Endpoints will be reported combined (Net Adverse Clinical Events; Major Adverse Cardiac or Cerebrovascular Events) and separately. The primary analysis will include all available follow-up time corresponding to a maximum follow-up time of 3 years and 2 months. CONCLUSION: HELP-MI SWEDEHEART aims to determine the utility of routine H. pylori screening to reduce UGIB and improve cardiovascular outcomes after MI. By integrating national registry follow-up data with a pragmatic trial design, it has the potential to provide evidence for the effect of the implementation of routine H. pylori screening as part of acute MI care. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05024864.
No takes yet. Share an insight, caveat, or question.
Hofmann et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: